LSL Pharma GroupTSXV:LSL -7.35%50 3-Year ROIIC % is 11.38 as of Dec. 2025, which is 437% above its 10-year median of 2.12. GuruFocus rates TSXV:LSL with a GF Score™ of 50/100 and a GF Value™ of C$0.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 944 Drug Manufacturers companies, LSL Pharma Group ranks better than 61.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
LSL Pharma Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 11.38%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for LSL Pharma Group's 3-Year ROIIC % or its related term are showing as below:
TSXV:LSL's 3-Year ROIIC % is ranked better than 61.33% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs TSXV:LSL: 11.38
LSL Pharma Group (TSXV:LSL) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
LSL Pharma Group 3-Year ROIIC % Related Terms
LSL Pharma Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for LSL Pharma Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LSL Pharma Group 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where LSL Pharma Group's 3-Year ROIIC % falls into.
LSL Pharma Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.258025 (Dec. 2025) - -6.757 (Dec. 2022) )
/
( 67.966 (Dec. 2025) - 28.417 (Dec. 2022) )
=
4.498975
/
39.549
=
11.38%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
LSL Pharma Group (TSXV:LSL) has a 3-Year ROIIC % of 11.38 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on LSL Pharma Group and its competitors. This is 437% above median its historical median of 2.12. According to the industry distribution chart, LSL Pharma Group ranks #365 out of 944 companies in the Drug Manufacturers industry, placing it in the top 38.7%.
Is LSL Pharma Group's 3-Year ROIIC % too high?
LSL Pharma Group's current 3-Year ROIIC % of 11.38 is 437% above median its 10-year median of 2.12. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. LSL Pharma Group's value of 11.38 is 213.1% above this industry median. Based on the distribution chart, LSL Pharma Group ranks #365 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, LSL Pharma Group has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, LSL Pharma Group ranks #365 out of 944 companies for 3-Year ROIIC %. This puts LSL Pharma Group in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. LSL Pharma Group's value of 11.38 is 213.1% above this benchmark. While the company's 10-year median is 2.12 vs. the industry median of 3.64, LSL Pharma Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LSL Pharma Group's current 3-Year ROIIC % of 11.38 is 213.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on LSL Pharma Group and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LSL Pharma Group's current 3-Year ROIIC % is 11.38, which is 437% above median its own 10-year median of 2.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.73, compared to a current price of C$0.32 — trading 56.8% below its estimated fair value. The current 3-Year ROIIC % is 11.38, which is 437% above median its 10-year median of 2.12 and 213.1% above the Drug Manufacturers industry median of 3.64. LSL Pharma Group's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current 3-Year ROIIC % is 11.38 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?
Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued.
The current stock price of C$0.32 is trading 56.8% below its estimated GF Value™ of C$0.73.
GuruFocus considers LSL Pharma Group to be Possible Value Trap.
Key valuation signals for TSXV:LSL:
3-Year ROIIC %: 11.38 (437% above median its 10-year median of 2.12)
GF Value™: C$0.73 vs. price of C$0.32 (56.8% below fair value)
Industry Position: 213.1% above the Drug Manufacturers median (#365 of 944)
No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
50GF Score
Get the complete analysis for TSXV:LSL
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:LSL has been successfully added to your 
